Kissei Pharmaceutical Co., Ltd. (TYO:4547)
Japan · Delayed Price · Currency is JPY 3,890.00
+15.00 (0.39%)
May 29, 2026, 3:30 PM JST
Kissei Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 97,406 | 88,330 | 75,579 | 67,493 | 65,381 | |
Revenue Growth (YoY) | 10.27% | 16.87% | 11.98% | 3.23% | -5.30% |
Cost of Revenue | 51,587 | 44,265 | 38,238 | 35,118 | 34,143 |
Gross Profit | 45,819 | 44,065 | 37,341 | 32,375 | 31,238 |
Selling, General & Admin | 48,745 | 22,179 | 20,790 | 20,289 | 19,923 |
Research & Development | - | 12,889 | 9,474 | 10,391 | 10,363 |
Other Operating Expenses | - | 129 | 143 | 149 | 137 |
Operating Expenses | 48,745 | 38,291 | 33,324 | 33,518 | 32,640 |
Operating Income | -2,926 | 5,774 | 4,017 | -1,143 | -1,402 |
Interest Expense | -28 | -21 | -18 | -20 | -23 |
Interest & Investment Income | 1,742 | 1,449 | 1,318 | 1,402 | 1,586 |
Currency Exchange Gain (Loss) | -363 | -229 | -103 | 186 | -60 |
Other Non Operating Income (Expenses) | 16 | 29 | 35 | 57 | 280 |
EBT Excluding Unusual Items | -1,559 | 7,002 | 5,249 | 482 | 381 |
Merger & Restructuring Charges | 371 | - | - | - | - |
Gain (Loss) on Sale of Investments | 17,377 | 11,719 | 9,119 | 13,133 | 16,161 |
Gain (Loss) on Sale of Assets | 701 | -215 | 80 | 63 | -35 |
Asset Writedown | - | -2,895 | - | - | - |
Other Unusual Items | - | -2 | -1 | 1 | -1 |
Pretax Income | 16,890 | 15,609 | 14,447 | 13,679 | 16,506 |
Income Tax Expense | 2,930 | 3,634 | 3,159 | 3,046 | 3,475 |
Earnings From Continuing Operations | 13,960 | 11,975 | 11,288 | 10,633 | 13,031 |
Minority Interest in Earnings | -181 | -14 | -128 | -105 | -110 |
Net Income | 13,779 | 11,961 | 11,160 | 10,528 | 12,921 |
Net Income to Common | 13,779 | 11,961 | 11,160 | 10,528 | 12,921 |
Net Income Growth | 15.20% | 7.18% | 6.00% | -18.52% | 144.48% |
Shares Outstanding (Basic) | 42 | 44 | 45 | 46 | 46 |
Shares Outstanding (Diluted) | 42 | 44 | 45 | 46 | 46 |
Shares Change (YoY) | -4.72% | -3.62% | -1.86% | - | -1.18% |
EPS (Basic) | 331.53 | 274.20 | 246.58 | 228.30 | 280.19 |
EPS (Diluted) | 331.53 | 274.20 | 246.58 | 228.30 | 280.19 |
EPS Growth | 20.91% | 11.20% | 8.01% | -18.52% | 147.41% |
Free Cash Flow | -6,368 | 2,014 | -2,878 | -8,782 | 44 |
Free Cash Flow Per Share | -153.22 | 46.17 | -63.59 | -190.44 | 0.95 |
Dividend Per Share | 120.000 | 100.000 | 82.000 | 80.000 | 56.000 |
Dividend Growth | 20.00% | 21.95% | 2.50% | 42.86% | 3.70% |
Gross Margin | 47.04% | 49.89% | 49.41% | 47.97% | 47.78% |
Operating Margin | -3.00% | 6.54% | 5.32% | -1.69% | -2.14% |
Profit Margin | 14.15% | 13.54% | 14.77% | 15.60% | 19.76% |
Free Cash Flow Margin | -6.54% | 2.28% | -3.81% | -13.01% | 0.07% |
EBITDA | 1,718 | 10,389 | 8,271 | 2,966 | 2,328 |
EBITDA Margin | 1.76% | 11.76% | 10.94% | 4.40% | 3.56% |
D&A For EBITDA | 4,644 | 4,615 | 4,254 | 4,109 | 3,730 |
EBIT | -2,926 | 5,774 | 4,017 | -1,143 | -1,402 |
EBIT Margin | -3.00% | 6.54% | 5.32% | -1.69% | -2.14% |
Effective Tax Rate | 17.35% | 23.28% | 21.87% | 22.27% | 21.05% |